<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293358</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000455625</org_study_id>
    <secondary_id>CCLG-GC-1997-01</secondary_id>
    <secondary_id>EU-20579</secondary_id>
    <secondary_id>SIOP-CNS-GCT-96</secondary_id>
    <nct_id>NCT00293358</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain</brief_title>
  <official_title>SIOP Intracranial Germ Cell Tumours Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin, etoposide, ifosfamide, and&#xD;
      cisplatin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill&#xD;
      tumor cells. Giving more than one drug (combination chemotherapy) with radiation therapy may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase III trial is studying combination chemotherapy followed by radiation&#xD;
      therapy to see how well it works compared to radiation therapy alone in treating patients&#xD;
      with germ cell tumors in the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate and compare, in a non-randomized protocol, reduced-dose craniospinal&#xD;
           radiotherapy alone or combination chemotherapy comprising carboplatin, etoposide&#xD;
           phosphate, and ifosfamide and local irradiation in patients with intracranial germinoma.&#xD;
&#xD;
        -  Increase survival with combination chemotherapy comprising cisplatin, etoposide&#xD;
           phosphate, and ifosfamide followed by focal radiotherapy or craniospinal irradiation in&#xD;
           patients with intracranial secreting germ cell tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Use the same diagnostic protocol for imaging and laboratory investigations before,&#xD;
           during, and after treatment.&#xD;
&#xD;
        -  Establish and use a common documentation system regarding general patient's data,&#xD;
           including diagnostic tests, clinical evaluation, surgery, histology, radiotherapy,&#xD;
           chemotherapy, and toxicity.&#xD;
&#xD;
        -  Collect information about toxicity, prognostic factors, and tumor markers.&#xD;
&#xD;
        -  Collect epidemiological data, including documentation of incidence and the site and the&#xD;
           histologic pattern of intracranial secreting and nonsecreting germ cell tumors in&#xD;
           children and adolescents.&#xD;
&#xD;
        -  Register associated malformations in the patients as well as the epidemiology of tumors&#xD;
           and malformations in relatives.&#xD;
&#xD;
      OUTLINE: This is a non-randomized, multicenter study. Patients are stratified according to&#xD;
      tumor classification (pure CNS germinoma vs secreting germ cell tumor and embryonal&#xD;
      carcinoma).&#xD;
&#xD;
      Patients in stratum I undergo biopsy or surgical resection and then begin radiotherapy with&#xD;
      or without chemotherapy.&#xD;
&#xD;
        -  Stratum I (pure CNS germinoma [without elevated markers]): Patients receive 1 of 2&#xD;
           treatment options based on national/center standard:&#xD;
&#xD;
             -  Option 1: Patients receive reduced-dose craniospinal radiotherapy 5 days a week for&#xD;
                3 weeks followed by a boost to the tumor bed 5 days a week for 2 weeks. Patients&#xD;
                with multifocal or metastatic disease receive additional boosts to the tumor sites.&#xD;
&#xD;
             -  Option 2: Patients receive carboplatin IV over 1 hour on day 1, etoposide phosphate&#xD;
                IV over 1 hour on days 1-3 and 22-24, and ifosfamide IV over 3 hours on days 22-26.&#xD;
                Treatment repeats every 6 weeks for 2 courses. After recovery from chemotherapy,&#xD;
                patients undergo radiotherapy 5 days a week for 5 weeks.&#xD;
&#xD;
        -  Stratum II (secreting tumors and embryonal carcinoma): Patients receive etoposide&#xD;
           phosphate IV over 1 hour on days 1-3, cisplatin IV over 1 hour on days 1-5, and&#xD;
           ifosfamide IV over 22 hours on days 1-5. Treatment repeats every 3 weeks for up to 4&#xD;
           courses. Patients whose tumor markers do not return to normal after completion of&#xD;
           chemotherapy are off protocol. Patients may undergo surgery after chemotherapy course 2&#xD;
           or 4 if required. After completion of chemotherapy and recovery from surgery, patients&#xD;
           with nonmetastatic disease undergo radiotherapy to the tumor bed 5 day a week for 6&#xD;
           weeks, and patients with metastatic disease undergo radiotherapy to the cerebrum, spinal&#xD;
           axis, and tumor bed for 7 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 4 weeks and then periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 500 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1997</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Clinical and radiological evidence of intracranial germ cell tumor, classified as 1 of&#xD;
             the following:&#xD;
&#xD;
               -  Germinoma&#xD;
&#xD;
                    -  Pure germinoma&#xD;
&#xD;
                    -  Germinoma with mature and/or immature teratoma&#xD;
&#xD;
               -  Secreting germ cell tumor&#xD;
&#xD;
                    -  Elevated tumor markers in serum and/or cerebral spinal fluid as evidenced by&#xD;
                       any of the following:&#xD;
&#xD;
                         -  Alpha-fetoprotein &gt; 25 ng/mL&#xD;
&#xD;
                         -  β-human choriogonadotropin &gt; 50 IU/L&#xD;
&#xD;
                    -  Any tumor containing 1 of these components:&#xD;
&#xD;
                         -  Yolk sac tumor&#xD;
&#xD;
                         -  Choriocarcinoma&#xD;
&#xD;
                         -  Embryonal tumor&#xD;
&#xD;
                              -  Normal tumor markers allowed&#xD;
&#xD;
          -  Diagnosis confirmed by histology or elevated serum markers&#xD;
&#xD;
          -  Metastatic or nonmetastatic disease&#xD;
&#xD;
               -  Two separate tumors in the suprasellar and pineal areas without evidence of&#xD;
                  metastatic disease elsewhere are considered nonmetastatic multifocal disease&#xD;
&#xD;
          -  Study treatment must begin ≤ 4 weeks after diagnosis&#xD;
&#xD;
          -  No pure immature or mature teratomas&#xD;
&#xD;
          -  The following additional patients are eligible:&#xD;
&#xD;
               -  Patients who are &gt; 18 years of age provided no other appropriate protocol exists&#xD;
&#xD;
               -  Patients who were diagnosed &gt; 4 weeks ago&#xD;
&#xD;
               -  Patients who are in relapse&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior treatment except surgery&#xD;
&#xD;
          -  No concurrent amino glycosides or other nephrotoxic drugs during ifosfamide&#xD;
             administration&#xD;
&#xD;
          -  No concurrent growth factors&#xD;
&#xD;
          -  No other concurrent chemotherapy or radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Nicholson, DM, MA, MRCPCH</last_name>
    <role>Study Chair</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie C. Baranzelli, MD</last_name>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_official>
    <last_name>U. Gobel, MD</last_name>
    <affiliation>Heinrich-Heine University, Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health at University of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester and Manchester Children's University Hospitals NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>childhood central nervous system choriocarcinoma</keyword>
  <keyword>childhood central nervous system embryonal tumor</keyword>
  <keyword>childhood central nervous system yolk sac tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

